The FDA on December 4, 2024, approved IMFINZI® for adults with Limited-Stage Small Cell Lung Cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. IMFINZI® is a product of AstraZeneca.
Bottom Ad
Advertisement
Subscribe
